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Cardiovascular (CV) disease is the leading cause of death and morbidity in patients with type
2 diabetes. Five CV risk factors (blood pressure, resting heart rate, body weight, cholesterol
levels and blood glucose) are monitored routinely as safety and efficacy endpoints in random-
ized clinical trials for diabetes therapies. To determine if different glucagon-like peptide-1
receptor agonists (GLP-1RAs) had varying effects on these CV risk factors, we reviewed
16 head-to-head trials directly comparing GLP-1RAs that included at least one of the five fac-
tors. Few trials reported statistical differences between GLP-1RAs in terms of systolic blood
pressure (SBP), body weight and total cholesterol. Liraglutide increased heart rate vs its com-
parators in three separate trials. All GLP-1RAs reduced glycated haemoglobin (HbA1c), but exe-
natide twice daily and lixisenatide had statistically smaller effects compared with other GLP-
1RAs. These descriptive data indicate that individual GLP-1RAs affect CV risk factors differ-
ently, potentially because of their individual pharmacokinetics and/or size. Short-acting GLP-
1RAs appeared to result in smaller changes in SBP and total cholesterol compared with
continuous-acting treatments, while large GLP-1RAs had a reduced effect on body weight com-
pared with small GLP-1RAs. For glycaemic control, short-acting GLP-1RAs had a greater impact
on postprandial glucose levels vs continuous-acting GLP-1RAs, but for fasting plasma glucose
levels and HbA1c, continuous-acting treatments had the greater effect. No differentiating
trends were obvious in heart rate data. These diverse actions of GLP-1RAs on CV risk factors
should aid individualized patient treatment.
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1 | INTRODUCTION
In 2015, the International Diabetes Federation estimated there were
415 million people with diabetes across the globe, and in high-income
countries up to 91% of those had type 2 diabetes.1 In patients with
type 2 diabetes, cardiovascular (CV) disease is the leading cause of
death and morbidity.1 The risk of developing CV disease is linked to
several factors, some of which are considered modifiable lifestyle risk
factors, including lack of physical exercise, smoking and diet.2,3 Other
risk factors are monitored routinely in clinical practice, and as safety
and efficacy endpoints in randomized clinical trials (RCTs), including
blood pressure,1 resting heart rate,4 body weight,5 cholesterol levels,1
and blood glucose.1 These monitored CV risk factors form the focus
of the present review.
Meta-analyses and population studies have examined how these
five monitored risk factors impact CV disease development, across
different populations, which have not always included patients with
type 2 diabetes. For example, a 10 mm Hg decrease in systolic blood
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pressure (SBP) reduces the risk of CV disease events by 11%.6 If rest-
ing heart rate increases to ≥83 beats per minutes (bpm), the risk of
CV death increases by 31%.7 Similarly, a 5-unit increase in body mass
index (BMI) results in a 16% increased risk of coronary heart disease5
and a 1-mmol/L decrease in LDL cholesterol reduces the annual rate
of CV disease by ~20%.8 Finally, a 0.9% decrease in glycated haemo-
globin (HbA1c) results in a significant reduction in non-fatal myocar-
dial infarction (MI) events by 17%.9 These specific numbers may be
relevant to particular population groups only in the cited references,
but as changes in each of these monitored factors are known to
decrease the risk of CV disease development, it is important to con-
sider how treatment of type 2 diabetes may influence them.
There are several treatment options available for patients with
type 2 diabetes, including glucagon-like peptide-1 receptor agonists
(GLP-1RAs).10–12 GLP-1RAs reduce hyperglycaemia by increasing
insulin secretion and decreasing glucagon secretion in a glucose-
dependent manner.11 The glucose-dependent nature of these actions
means that hyperglycaemia is reduced with a low risk of hypoglycae-
mia.11 Through their impact on the GLP-1 signalling pathway, this
class of agonists also facilitates weight loss and exerts effects on sev-
eral CV variables.13
Currently, there are six GLP-1RAs approved for the treatment of
patients with type 2 diabetes in the USA and Europe: exenatide twice
daily14,15; exenatide once weekly16,17; lixisenatide once daily18,19; lir-
aglutide once daily20,21; albiglutide once weekly22,23; and dulaglutide
once weekly.24,25 Data from phase III studies of other (currently
unapproved) GLP-1RAs, semaglutide and ITCA 650 are also
available.26–28 ITCA 650 is an osmotic miniature pump that continu-
ously releases exenatide to the subcutis for up to 12 months.29 Other
GLP-1RAs are in development (e.g. efpeglenatide30); however, there
are currently limited clinical data for these treatments.
In 2008, the US Food and Drug Administration issued guidelines
whereby the pharmaceutical industry must demonstrate that any new
treatment for patients with type 2 diabetes will not result in an unac-
ceptable increase in CV risk.31 Of the resulting CV outcome trials
(CVOTs; all completed in patients at high risk of CV disease), three
have published results with GLP-1RAs. The first trial demonstrated
that lixisenatide did not significantly affect the rate of major adverse
CV events vs standard care.32 The next two of these trials demon-
strated that liraglutide33 and semaglutide34 had a beneficial effect on
CV outcomes compared with current standard of care. Some other
GLP-1RA CVOTs have finished, but the data are yet to be published,
with only headline results from press releases available stating that
they are non-inferior vs placebo (for ITCA 650 in FREEDOM-CVO,
NCT0145589635 and for exenatide once weekly in EXSCEL,
NCT0114433836). Other CVOTs are ongoing, including REWIND
with dulaglutide (NCT01394952),37 HARMONY with albiglutide
(NCT02465515)38 and PIONEER-6 with oral semaglutide
(NCT02692716).39 It is uncertain if GLP-1RAs prevent the develop-
ment of CV disease in patients with low CV risk.40
While treatment guidelines consider GLP-1RAs as one treatment
class,10,11 there are some intrinsic differences between the molecules
in their pharmacokinetics, structure and size (Table 1), which may
influence their impact on CV disease. To determine if the different
GLP-1RAs had varying effects on CV risk factors, the published litera-
ture was searched for head-to-head trials directly comparing GLP-
1RAs and detailing at least one of the five CV risk factors of interest:
blood pressure; heart rate; body weight; lipid profile; and glycaemic
control. We were also interested in inflammation markers, but as
measurements of inflammation do not yet form part of routine RCT
practice in patients with type 2 diabetes, we used the identified trials
to determine if any such head-to-head data exist.
2 | SEARCHES PERFORMED AND TRIALS
INCLUDED
The 6 GLP-1RAs approved for the treatment of patients with type
2 diabetes and semaglutide with a published head-to-head study
formed the focus of the initial literature searches. PubMed was
searched using the following search strings, with the filter of “clinical
trial” from inception to March 20, 2017 (ie, the cut-off date for this
review):
a. (lixisenatide AND exenatide) OR (lixisenatide AND liraglutide)
OR (lixisenatide AND albiglutide) OR (lixisenatide AND dulaglu-
tide) OR (lixisenatide AND semaglutide): 3 hits and all
3 included
b. (exenatide [ti] AND liraglutide [ti]) OR (exenatide [ti] AND albiglu-
tide [ti]) OR (exenatide [ti] AND dulaglutide [ti]) OR (exenatide
[ti] AND semaglutide [ti]): 7 hits, 3 included (4 excluded:
1 detailed glucose fluctuations only, 1 lipidaemia only, 1 patient-
reported outcomes only, 1 was a switching study and so the data
were not directly relevant)
TABLE 1 Classification of GLP-1RAs according to their pharmacokinetics, structure and size
Pharmacokinetics Structure Size
Short-acting Continuous-acting Exendin-4-based GLP-1-based Small (<5 kDa)
Large
(~63–73 kDa)
Exenatide twice daily14 Albiglutide22 Exenatide twice daily14 Albiglutide22 Exenatide twice daily14 Albiglutide22
Lixisenatide18 Dulaglutide24 Exenatide once weekly41 Dulaglutide24 Exenatide once weekly16 Dulaglutide24
Exenatide once weekly16 ITCA 65029 Liraglutide20 ITCA 65029
ITCA 65029 Lixisenatide41 Semaglutide26,42 Liraglutide20
Liraglutide20 Lixisenatide18
Semaglutide26,42 Semaglutidea26,42
a Precise molecular weight is not included in the cited references, but it is referred to as a small molecule.
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c. (liraglutide [ti] AND albiglutide [ti]) OR (liraglutide [ti] AND dula-
glutide [ti]) OR (liraglutide [ti] AND semaglutide [ti]): 5 hits and all
5 included
d. (albiglutide [ti] AND dulaglutide [ti]) OR (albiglutide [ti] AND
semaglutide [ti]): 0 hits
e. (dulaglutide [ti] AND semaglutide [ti]): 0 hits
f. (exenatide once weekly [ti] AND twice daily [ti]): 5 hits, 2 included
(3 excluded: 1 excluded as a pooled analysis study; 1 as it was
patient-reported outcomes; and 1 as it was a post hoc analysis)
This provided 12 studies (one with two publications) for inclu-
sion; however, we were aware of other head-to-head studies not
identified through this search from reading other review articles and
attending congresses. These four studies were:
i. the Lira-Lixi study,43 which was removed by the “clinical trial”
filter;
ii. Rosenstock et al.’s study on albiglutide,44 which did not contain
exenatide in its title;
iii. SUSTAIN-3,45 which has been presented at a congress only;
iv. Nakatani et al.,46 which did not list any of the GLP1-RAs by
name in its title.
In total, 16 trials were identified; 15 of which recorded several of
the CV risk factors and one focused solely on heart rate and ECG
outputs46 (Table 2). All were multicentre studies with >100 patients
enrolled, apart from the Nakatani et al.46 study that recruited
60 patients from a single site in Japan. The results from all 16 studies
are compared in the present review, acknowledging that cross-trial
comparisons should always be conducted with caution, and being
aware of the limitations such as differences in study populations and
trial design, including the use of concomitant medications.
3 | BLOOD PRESSURE
According to a report by Lim et al.,59 hypertension is one of the lead-
ing risk factors globally for disease burden.59 To aid accurate mea-
surements of blood pressure, the Joint National Committee on the
Prevention, Detection, Evaluation and Treatment of High Blood Pres-
sure has published guidelines.60 Very few of the included studies
detailed the specific methods used to measure blood pressure; these
were: LEAD-6 followed national guidelines48,60; Kapitza et al.55 mea-
sured blood pressure when patients were in a supine resting position
and before treatment injection; in the Lira-Lixi trial, measurements
were according to standard clinical practice43; Miyagawa et al. (and
Odawara et al. in the extension) used seated blood pressure measure-
ments57,58; and Meier et al.56 measured the mean 24-hour day and
night SBP and diastolic blood pressure (DBP).
Two trials reported a significant treatment difference in SBP
between two continuous-acting GLP-1RAs (Figure 1).45,58 Liraglutide
0.9 mg once daily decreased SBP significantly more than dulaglutide
0.75 mg once weekly at 26 weeks and 52 weeks (P = .013 and
P = .007, respectively),57,58 and semaglutide 1.0 mg once weekly also
significantly decreased SBP compared with exenatide 2 mg once
weekly at 56 weeks (P = .016).45 Both of these studies had the lon-
gest duration out of the included trials (52 and 56 weeks, respec-
tively).45,58 These were the only two trials that used these specific
doses of liraglutide and semaglutide. In the other 12 trials, there were
no significant differences reported between the GLP-1RAs investi-
gated (Figure 1). For DBP, no significant between-treatment differ-
ences were reported in any of the included trials.42–45,47–58
4 | HEART RATE
Methods used to measure heart rate were detailed in just three publi-
cations: Kapitza et al.55used ECG measurements, after 10 minutes’
rest in the supine position, before injection of the study drug; Meier
et al.56 monitored heart rate over 24 h (including day and night
means); and Nakatani et al.46 used a 24-hour Holter ECG.
In 8 of the 9 trials with liraglutide, the increases in heart rate it
induced were numerically larger than with comparators43,46,48,52,54–57
and in three of these the differences were significant (P ≤ .0012 in all
three trials)43,48,56 (Figure 2). In the remaining trial with liraglutide,
semaglutide 1.6 mg once weekly resulted in a larger heart rate
increase from baseline than liraglutide 1.8 mg once daily.42 There
were no other statistically significant differences in heart rate
reported with the other GLP-1RAs investigated in these head-to-
head trials at the primary endpoint (Figure 2).
In two trials, differences in heart rate observed between GLP-
1RAs were not sustained over time. In AWARD-1, dulaglutide once
weekly significantly increased heart rate at week 26 (+2.8 bpm, both
doses) compared with exenatide 10 μg twice daily (+1.2 bpm; P < .05
for both dulaglutide 0.75 mg and 1.5 mg once weekly), but at week
52 there were no significant differences between these GLP-1RA
treatments or compared with placebo.53 In HARMONY-7, there was
a transient increase in heart rate of 5.7 bpm at week 4 with liraglu-
tide treatment, which was not evident in the albiglutide treatment
arm. At week 32, the changes from baseline were smaller (+3 bpm
with liraglutide and +1 bpm with albiglutide).52 In light of this obser-
vation, it should be noted that the 13.2 bpm increase reported by
Nakatani et al.46 with liraglutide 0.9 mg once daily was measured
after 1 week of treatment with this dose and so may not be indica-
tive of any long-term change in this CV risk factor.
5 | BODY WEIGHT
Statistical comparisons showed that liraglutide 1.8 mg once daily
resulted in a significantly greater decrease in body weight from base-
line compared with exenatide 2 mg once weekly,50 albiglutide 50 mg
once weekly,52 dulaglutide 1.5 mg once weekly54 and lixisenatide
20 μg once weekly,55 in four separate trials (Figure 3). In an additional
three trials, there were no significant between-treatment differences
in body weight between liraglutide 1.8 mg once daily and exenatide
10 μg twice daily48 or lixisenatide 20 μg once daily43,56 (Figure 3).
The decrease in body weight achieved with semaglutide 1.0 mg once
weekly was significantly greater than that achieved with exenatide
2 mg once weekly (P < .0001)45 and numerically greater than that
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achieved with liraglutide 1.8 mg once daily42 (estimated treatment
difference = −2.2 kg; 95% confidence interval [CI] –3.2 to −1.3, but
not corrected for multiple testing; Figure 3).
6 | LIPID PROFILES
Lipid profiles were reported in 10 of the 16 trials included in this
review42–44,47–50,52,54,57,58 (Figure 4); however, two of the trials
reported the lipid profiles in a manner that did not allow them to be
plotted on Figure 4 (Nauck et al. only provided lipid data for semaglu-
tide and not liraglutide,42 while the Lira-Lixi study reported ratios
based on decrease from baseline43). Only 4 of the 10 trials specifi-
cally stated that fasting lipids were measured.42,43,47,49 As the other
trials included the measurement of fasting plasma or serum glucose,
we have assumed that the lipid profiles were measured using the
same blood samples and represent fasting lipid profiles of the
patients.44,48,50,52,54,57 Within these 10 trials, total cholesterol and
HDL cholesterol were reported in all,42–44,47–50,52,54,57 nine trials
TABLE 2 Head-to-head GLP-1RA trials included in this review article
Trial GLP1-RAs investigated Study duration Study type
Randomization
ratio
Number
of
patients
Location(s)
DURATION-
147
Exenatide 2 mg once weekly vs
exenatide 10 μg twice daily
30 wk Randomized, open-label,
non-inferiority
1:1 303 Canada, USA
LEAD-648 Liraglutide 1.8 mg once daily vs
exenatide 10 μg twice daily
26 wk Randomized, open-label 1:1 464 Multinational
DURATION-
549
Exenatide 2 mg once weekly vs
exenatide 10 μg twice daily
24 wk Randomized, open-label 1:1 254 USA
DURATION-
650
Exenatide 2 mg once weekly vs
liraglutide 1.8 mg once daily
26 wk Randomized, open-label 1:1 912 Multinational
GetGoal-X51 Lixisenatide 20 μg once daily vs
exenatide 10 μg twice daily
24 wk Phase III, randomized,
open-label
1:1 639 Multinational
HARMONY-
752
Albiglutide 50 mg once weekly
vs liraglutide 1.8 mg once
daily
32 wk Phase III, randomized,
open-label, non-
inferiority
1:1 812 Multinational
AWARD-153 Dulaglutide 1.5 mg or 0.75 mg
once weekly vs exenatide
10 μg twice daily
52 wk in total
(primary
endpoint at
26 wk)
Randomized, placebo-
controlled, double
blind
2:2:2:1 978 Mexico,
Argentina,
USA
AWARD-654 Dulaglutide 1.5 mg once weekly
vs liraglutide 1.8 mg once
daily
26 wk Phase III, randomized,
open-label
1:1 599 Multinational
Lira-Lixi43 Liraglutide 1.8 mg once daily vs
lixisenatide 20 μg once daily
26 wk Randomized, open-label 1:1 404 Multinational
Rosenstock
et al.44
Albiglutide 4, 15, 30 mg once
weekly vs albiglutide 15, 30,
50 mg every second week vs
albiglutide 50 or 100 mg
monthly vs exenatide 10 μg
twice dailya
16 wk treatment
followed by
11 wk wash-
out
Phase II, randomized,
placebo-controlled,
double blind
(10 treatment
arms)a
361 Chile,
Dominican
Republic,
Mexico,
USA
Nauck
et al.42
Semaglutide 0.1, 0.2, 0.4, 0.8 mg
and 0.8, 1.6 mg with dose
escalation once weekly vs
liraglutide 1.2, 1.8 mg once
dailya
12 wk Phase II, randomized,
placebo controlled,
blind (semaglutide vs
placebo), open-label
liraglutide
(9 treatment
arms)a
415 Multinational
Kapitza
et al.55
Lixisenatide 20 μg once daily vs
liraglutide 1.8 mg once daily
28 days Randomized, open-label 1:1 148 Germany
Meier et al.56 Lixisenatide 20 μg once daily vs
liraglutide 1.2, 1.8 mg once
dailya
8 wk Randomized, open-label 1:1:1a 142 Germany
Miyagawa
et al.57
(and
Odawara
et al.58)
Dulaglutide 0.75 mg once
weekly vs liraglutide 0.9 mg
once daily
26 wk
(52-wk results
reported in58)
Randomized, blind
(dulaglutide vs
placebo), open-label
liraglutide
4:2:1
(dulaglutide:
liraglutide:
placebo)
492 Japan
SUSTAIN-
345
Exenatide ER 2.0 mg once
weekly vs semaglutide 1.0 mg
once weekly
56 wk Phase III, randomized,
open-label
1:1 813 Europe, USA
Nakatani
et al.46
Lixisenatide 20 μg once daily vs
liraglutide 0.9 mg once daily
A minimum of
1 wk at the
maximum dose
Randomized, open-label
(heart rate/ECG)
1:1 60 Japan
(single centre)
Abbreviations: ER, extended-release.
a To aid comparisons in this review, only the highest doses of the GLP-1-RA were included in subsequent figures.
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reported LDL cholesterol42–44,47–50,52,54 and nine reported
triglycerides.42–44,47–49,52,54,57,58 Other lipids examined included
VLDL cholesterol,42,43,48 free fatty acids,43,44,48,52 non-HDL choles-
terol50,54 and apolipoprotein B.48
Just one trial reported a statistically significant difference
between two GLP-1RAs and placebo (Figure 4).49 In DURATION-5,
exenatide 2 mg once weekly statistically reduced total and LDL cho-
lesterol levels from baseline (−0.40 and −0.17 mmol/L, respectively),
but exenatide 10 μg twice daily did not (+0.02 and +0.07 mmol/L,
respectively; P < 0.01, for comparison between the two treat-
ments).49 In LEAD-6, liraglutide was associated with significantly
greater reductions in triglycerides and free fatty acid values compared
with exenatide 10 μg twice daily (P < .05, P < .01, respectively); how-
ever, VLDL cholesterol increased by 0.20 mmol/L in the liraglutide
group and by 0.27 mmol/L in the exenatide group (treatment differ-
ence = −0.07 mmol/L; P = .028).48
7 | GLYCAEMIC CONTROL
Statistically significant differences in HbA1c between the GLP-1RAs
were reported in several of the trials,43,45,47–50,53,55,56 three trials
FIGURE 1 Change in systolic blood pressure in head-to-head comparison trials of GLP-1RAs. Only significant P values are included. *To aid
comparisons in this review, only the highest doses of the GLP-1RA in any given dosing schedule in these trials were included. NR, not reported
FIGURE 2 Change in heart rate in head-to-head comparison trials of GLP-1RAs. Only significant P values are included. *To aid comparisons in
this review, only the highest doses of the GLP-1RA in any given dosing schedule in these trials were included
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were of non-inferiority design,51,52,54 two did not complete formal
statistical comparisons between the GLP-1RAs tested42,44 and one
trial did not measure HbA1c (as it focused on heart rate)46 (Figure 5).
In five of the six trials that included exenatide 10 μg twice daily, the
HbA1c response was smaller with it than with comparators (P < .01
vs exenatide 2 mg once weekly47,49; P < .01 vs liraglutide 1.8 mg
once daily48; P < .01 vs dulaglutide 1.5 mg once weekly and 0.75 mg
once weekly53; no between-treatment statistics were reported vs
albiglutide 30 mg once weekly and 50 mg every second week44).
The remaining trial with exenatide twice daily demonstrated the
FIGURE 3 Change in body weight in head-to-head comparison trials of GLP-1RAs. Only significant P values are included. *To aid comparisons
in this review, only the highest doses of the GLP-1RA in any given dosing schedule in these trials were included. †P-value not reported for
weight difference of 1.02 kg (95% CI: 0.456 to 1.581). ‡Mean change greater for semaglutide 1.6 mg vs liraglutide 1.8 mg based on the
unadjusted CI (treatment difference: −2.2 kg [95% CI –3.2 to −1.3])
FIGURE 4 Change in total cholesterol levels in head-to-head comparison trials of GLP-1RAs. Only significant P values are included. *To aid
comparisons in this review, only the highest doses of the GLP-1RA in any given dosing schedule in this trial were included. †Cholesterol was
reported in mg/dL in the publication and so was converted to mmol/L for this figure. NR, not reported
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non-inferiority of lixisenatide 20 μg once daily to exenatide 10 μg
twice daily.51
In three separate trials, the HbA1c improvements with lixisena-
tide 20 μg once daily were significantly smaller compared with liraglu-
tide 1.8 mg once daily (P < .01 for all).43,55,56 Liraglutide 1.8 mg also
had a greater impact on HbA1c vs exenatide 10 μg twice daily48 and
exenatide 2 mg once weekly,50 but not compared with semaglutide
1.6 mg once weekly42 or dulaglutide 1.5 mg once weekly54
(Figure 5).
At least one other measure of glycaemic control (fasting plasma
glucose [FPG], fasting serum glucose [FSG], or postprandial plasma
glucose [PPG] levels) was reported in all but one of the included
trials.42–45,47–57 The 15 trials that reported HbA1c also included FPG
or FSG levels.42–45,47–57 In the majority of these, if a significant treat-
ment difference between two GLP-1RAs was reported in HbA1c, a
similar difference was found in FPG or FSG levels42,43,45,47–52; how-
ever, this was not the case in two trials. In the study by Meier
et al.,56 there was a significant difference between liraglutide 1.8 mg
once daily and lixisenatide 20 μg once daily for HbA1c, but no differ-
ence in FPG levels. Similarly in the GetGOAL-X trial, the difference in
HbA1c between lixisenatide 20 μg once daily and exenatide 10 μg
twice daily appeared significant as the 95% CI did not cross zero
(treatment difference: 0.17%, 95% CI 0.033 to 0.297) and the two
GLP-1RAs were similar in FPG levels (treatment difference:
0.23 mmol/L, 95% CI –0.052 to 0.522).51
Ten of the trials reported PPG levels,42,43,45,47,48,53–56,58 five of
which used the 7-point self-monitored plasma glucose
(SMPG),45,47,48,54,58 three used the area under the curve after the
start of a standardized breakfast test meal,42,55,56 one used the 8-
point SMPG53 and one the 9-point SMPG.43 In six of these, the
trends were in the opposite direction to HbA1c, where treatments
with larger reductions in HbA1c had smaller reductions in PPG com-
pared with the comparators within any particular trial.42,43,47,48,55,56
The majority of these trials also showed that there was a tendency
for short-acting treatments to reduce PPG more than continuous-
acting treatments, while continuous-acting treatments reduced
FPG/FSG more than their short-acting counterparts.43,47,48,55,56
8 | INFLAMMATION
While the focus of the present review was the CV risk factors rou-
tinely monitored in RCTs, other CV risk factors exist, including the
presence of inflammation markers within patient samples.3 A meta-
analysis of data from >200 000 patients demonstrated a strong cor-
relation between C-reactive protein (CRP) levels and the develop-
ment of CV disease,61 but many studies of other markers were
limited by possible reporting bias.62 It is, therefore, considered at pre-
sent that CRP is the only inflammatory marker with a proven link to
CV risk.3 Of the 16 trials included in this review, DURATION-6 was
the only trial to publish CRP levels (with a high sensitivity assay).50
CRP levels improved in both treatment arms (exenatide 2 mg once
weekly and liraglutide 1.8 mg once daily) by similar amounts (treat-
ment difference: −2.48 nmol/L; 95% CI –14.83 to 9.43).50
9 | DISCUSSION
It is well established that all GLP-1RAs improve glycaemic
control42–45,47–57 and the present comparison of head-to-head trials
shows that they also improve three of the other four CV risk factors
examined (decreased blood pressure, total cholesterol and body
FIGURE 5 Change in HbA1c in head-to-head comparison trials of GLP-1RAs. *To aid comparisons in this review, only the highest doses of the
GLP-1RA in any given dosing schedule in these trials were included. †Non-inferiority P value not reported (95% CI 0.033 to 0.297, meeting
predefined non-inferiority margin). ‡Non-inferiority P value = .0846 (not meeting predefined non-inferiority margin). §For both doses of
dulaglutide vs exenatide twice daily. ¶Non-inferiority P value <.001 (meeting predefined non-inferiority margin). ¶¶Mean change greater for
semaglutide vs liraglutide based on the unadjusted CI
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weight). However, all GLP-1RAs increased heart rate from baseline,
but liraglutide 1.8 mg once daily was the only GLP-1RA to do so sta-
tistically significantly vs its comparators in three trials. Through the
descriptive comparisons made here, it would appear that the individ-
ual GLP-1RAs affect CV risk factors differently, potentially because
of individual pharmacokinetics, molecular structure or size, thereby
possibly complicating any treatment class effects. The diverse actions
of GLP-1RAs on CV risk factors mean that they can be used to tailor
treatments for patients based on their individual needs and may also
partly explain the different results from the published GLP-1RA
CVOTs.
9.1 | Pharmacokinetics: duration of biological
activity
As there were no statistically significant differences in blood pressure
in estimated treatment differences between short- and continuous-
acting GLP-1RAs, we examined the changes from baseline to deter-
mine if perhaps any underlying trend existed in this classification of
GLP-1RAs. Short-acting GLP-1RAs (exenatide twice daily and lixise-
natide once daily) appeared to result in smaller changes from baseline
in SBP compared with continuous-acting treatments (exenatide once
weekly, liraglutide once daily, albiglutide once weekly and every sec-
ond week, dulaglutide once weekly, semaglutide once weekly). For
total cholesterol, the only reported significant difference between
two molecules was between exenatide twice daily and exenatide
once weekly, with the continuous-acting GLP-1RA inducing the larger
decrease.49 A possible underlying reason to explain this could be that
short-acting treatments are associated with shorter exposure and,
thus, intermittent increases in GLP-1 receptor activity, whereas
continuous-acting agonists ensure 24-hour exposure and, thus, con-
tinuously increased receptor activity.13
There were no obvious trends in heart rate when results from
treatment with continuous-acting vs short-acting molecules were
compared, apart from the continuous-acting liraglutide 1.8 mg once
daily resulting in greater statistically significant increases vs short-
acting exenatide twice daily48 and lixisenatide once daily.43,56
Changes in heart rate may be sensitive to the precise timing of the
measurement, in that if the heart rate of a patient on a short-acting
treatment is measured just prior to a dose, no obvious effect may be
detected. This was evident from the hourly heart rate measurements
reported by Meier et al.56 and Nakatani et al.46; however, over the
course of several weeks, it would appear that the initial increases in
heart rate reported with continuous-acting treatments decline,52,53
which is suggestive of some treatment tolerability or tachyphylaxis
for this particular CV risk factor.
For glycaemic control measurements, it appeared that
continuous-acting treatments had a greater effect on HbA1c and
FPG vs short-acting treatments, but for PPG, short-acting GLP-1RAs
had the greater effect, as described previously.13 The impact of these
two specific glycaemic factors on CV disease risk is unknown.
Improvements in blood pressure and glycaemic control are
known to improve diabetes-related death, microvascular disease,
stroke, MI and nephropathy63–65; however, the included studies were
generally 26 weeks in duration, so it remains difficult to know how
between-group differences in the effects of GLP-1RAs on CV risk
factors may impact patient CV outcomes. These outcomes may not
be apparent until several years after initiating treatment with these
agonists.
A comparison between CVOTs (typically 2–5 years in duration)
and these head-to-head trials may indicate the impact that changes
in the five risk factors may have on CV outcomes. Again, such cross-
trial comparisons need to be made with care because of differences
in study design, particularly inclusion criteria. Three CVOTs have
examined the impact of GLP-1RAs on major adverse CV events,
including death from CV causes, non-fatal MI or non-fatal stroke with
a median 2–3 years of follow-up.32–34 These trials showed that the
continuous-acting GLP-1RAs liraglutide and semaglutide reduce the
risk of major adverse CV events compared with standard care,33,34
while the short-acting GLP-1RA lixisenatide does not have a signifi-
cant impact on these events compared with standard care.32 Within
these longer-term CVOTs, SBP, glycaemic control, body weight and
heart rate showed similar changes as in the head-to-head compari-
sons. However, it is interesting to note that the reported time points
for these parameters in these three publications varied as follows: lix-
isenatide 20 μg once daily at week 12,32 liraglutide 1.8 mg once
daily (significant differences compared with placebo for the four
parameters noted) at month 3633 and semaglutide (significant differ-
ences in all four) at week 104.34 Each of these comparisons was vs
placebo with standard of care, which included other glucose-
lowering treatment, dependent on the trial protocol. Cholesterol
levels were only reported in SUSTAIN-6, and the changes were sig-
nificant with semaglutide 0.5 mg once weekly and not the 1.0 mg
once-weekly dose vs placebo.34 In addition to the different study
populations and intrinsic study design differences, the question
arises as to whether the results of the CVOTs are attributable to dif-
ferences in the effects of liraglutide, semaglutide and lixisenatide on
these CV risk factors alone or to other factors, for example, other
pharmacological or cardioprotective mechanisms (e.g. reductions in
atherosclerosis).
9.2 | Molecular structure (exendin-4-based vs
human GLP-1-based)
The molecular structure of the treatments did not appear to have an
impact on any of the five CV risk factors examined, with no apparent
trends between exendin-4-based (exenatide twice daily, exenatide
once weekly and lixisenatide14,16,18) or human GLP-1-based (liraglu-
tide, albiglutide, dulaglutide and semaglutide20,22,24) treatments. As
the precise signalling pathways between GLP-1 and CV risk factors
have yet to be determined,66 it is unknown how these two different
molecular structures may affect the pathways.
The immunogenicity of these treatments appears to be related to
their molecular structure, with some GLP-1RA treatments more
immunogenic than others.13 The proportion of patients with anti-
bodies after treatment with exendin-4-based GLP-1RAs ranges from
44% to 70%.15,17,19 This proportion is lower after treatment with
GLP-1 analogues (range from 1.6% to 8.6%).21,23,25 As there did not
appear to be a link between structure and CV risk factors, it would
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also appear that the presence of antibodies to the treatments does
not play a role here.
Results from ongoing CVOTs of GLP-1RAs will also be informa-
tive in this research area. To date, three CVOTs have shown that
three exendin-based therapies (lixisenatide,32 ITCA 65035 and exena-
tide once weekly36) are non-inferior compared with placebo for CV
outcomes. Two other CVOTs showed that two GLP-1-based thera-
pies (liraglutide33 and semaglutide34) may have cardioprotective
effects. It will be interesting to see the full results of the EXSCEL
(exenatide once weekly) study, as it is a continuous-acting GLP-1RA,
but only its non-inferiority to placebo has been reported.36 Other
ongoing CVOTs may help determine if molecular structure or activity
duration of GLP-1RAs is correlated with CV benefit.
9.3 | Size
The molecular weight of GLP-1RAs appeared to influence their
impact on body weight and heart rate, which was reflected in the sig-
nificant treatment differences reported in some of the head-to-head
trials. In the included studies, large GLP-1RAs (>60 kDa; albiglutide
and dulaglutide) had a reduced effect on body weight compared with
smaller GLP-1RAs (<5 kDa; exenatide twice daily, exenatide once
weekly, liraglutide, lixisenatide and semaglutide). Their impact on
heart rate followed a similar trend, but it remains unknown if there is
any link between the two parameters. Although it is commonly
believed that only molecules <500 Da are able to cross the blood–
brain barrier,67 there is evidence that lixisenatide, liraglutide and exe-
natide can effect neuronal function, either by crossing the blood–
brain barrier or through interacting with GLP-1 receptors present in
circumventricular organs.68–70 It is possible that the larger GLP-1RAs
may not be able to penetrate into the brain and/or affect central ner-
vous system signalling to the same extent as the smaller
agonists,13,41,70 thereby reducing their known effects on satiety and
cardiomechanisms.41
It is interesting to note that, although the size of the molecule
tended to correlate with biological activity, i.e. the largest GLP-1RAs
having the longest half-lives,23,25 this was not the case for all treat-
ments because of different formulations. In particular, exenatide once
weekly has a molecular weight of just 4 kDa, but through the adher-
ence of exenatide to microspheres, it is released within the body for
up to 10 weeks.16 This disconnect between size and half-life may
explain some of the inconsistencies observed in some of the CV risk
factor trends.
9.4 | Clinically important differences
In the present narrative review, we focused on the statistical differ-
ences reported in the included publications; however, the size of
these differences compared with published minimal clinically impor-
tant differences are also worthwhile of consideration. While detailed
studies on blood pressure and lipid profiles have been published,6,8
the minimal clinically important differences in these CV risk factors in
patients with type 2 diabetes receiving treatments for blood glucose
are unknown.71 From the meta-analysis by Emdin et al.6 it would
appear that a 10-mm Hg decrease in SBP is beneficial for patients
with diabetes, but the largest statistical differences here were 2.7 mm
Hg57 and 2.4 mm Hg.45 Similarly, for lipids, the largest treatment dif-
ferences in total cholesterol were 0.42 mmol/L,44 which is unlikely to
be clinically significant. The minimal clinically important difference in
heart rate is also unknown and there remains debate in the field as to
whether it is an independent CV risk factor or not.72 For body weight,
patients with type 2 diabetes who are overweight are recommended
to lose 5% to 10% body weight as an initial goal, but smaller losses in
weight may also be beneficial71 and as such the clinically important
difference remains undetermined. The largest difference in body
weight between two GLP-1RAs in one trial was 3.7 kg, from a base-
line of 96 kg, representing a 3.9% loss in weight,45 which may have a
clinical impact. Finally, for HbA1c, a clinically minimal important differ-
ence of 0.5% is recognized.71 This magnitude difference was reported
in four of the trials (DURATION-5,49 AWARD-1,53 Lira-Lixi43 and
SUSTAIN-345), in which exenatide once weekly,49 dulaglutide,53
liraglutide43 and semaglutide45 were both statistically and clinically
significantly different from their comparators.
9.5 | Limitations
Narrative reviews, such as this, are inherently limited by lack of a fully
systematic approach and any additional analyses. While cross-trial
comparisons should always be made with caution because of differ-
ences in study design and baseline population demographics, investi-
gating the trends across these 16 trials has highlighted some areas
that could be examined in detail in future mechanistic studies, head-
to-head trials, network meta-analyses and outcomes models. The lack
of detail within the publications relating to methods used to measure
blood pressure, heart rate and lipids in particular also contributed to
making the comparisons difficult. For example, measurements per-
formed in the morning under fasting conditions would be unlikely to
capture any direct effect if a short-acting GLP-1RA was administered
12–24 hours before this. In contrast, 24-hour blood pressure mea-
surements would be expected to capture any effects of such
treatments.
Concomitant medication and prior CV events used as inclusion
and exclusion criteria in the trials may also have affected the results
presented here. Some publications specifically mentioned that lipid-
lowering medications had to be maintained at pre-enrolment doses
unless otherwise advised by the trial investigator (e.g. LEAD-649), but
others do not mention their use at all within the published eligibility
criteria (e.g. AWARD-153). Seven of the trials listed a CV-related
exclusion criterion,42,44,48,50–52,54 but there was no mention that CV
events were considered as an eligibility criterion in other
trials.43,45,47,49,53,55–57 The lack of details provided within the publica-
tions for the inclusion/exclusion criteria used for most of these trials
makes it difficult to suggest any hypotheses as to how these may
have impacted the results.
In terms of the CV risk factors examined, we were interested in
inflammation, but CRP levels were only published in one of the
trials.50 In the future, if further evidence emerges in favour of inflam-
matory markers as CV risk factors, it may be that they will be moni-
tored routinely in RCTs, as for the main risk factors included in this
review, but we were limited on this point by the available data. Lack
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of data also limited analysis of BMI, which is closely related to CV
disease.5 Within the context of head-to-head trials in type 2 diabetes,
it is body weight, and not BMI, that is commonly used as a study end-
point, which complicates this area.
A fundamental limitation of this narrative review is that just two
of the included 16 trials were double-blind in design44,53 and two
partially blinded.42,57,58 The other trials were open-label and so at risk
of bias, which has been demonstrated with other treatments.73–75 It
is unknown how this affected the reported results.
10 | CONCLUSION
The data reviewed here indicate that there may be differences
between short-acting and continuous-acting GLP-1RAs, and between
small and large GLP-1RA molecules in terms of their effects on CV risk
factors. Within the five CV risk factors investigated, the molecular
structure of the GLP-1RAs did not seem to have an effect; for now,
only GLP-1-based GLP-1RAs with continuous activity have shown
beneficial effects on CV outcomes. Improvements in CV risk factors
with these GLP-1RAs may contribute to these beneficial CV effects;
however, improvements in CV risk factors do not always translate into
improvements in CV outcomes, as has been shown with the short-
acting GLP-1RA lixisenatide. The mechanisms underlying reductions in
CV risk with certain GLP-1RAs merit further investigation.
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